|
Actavia Life Sciences Inc (RASP) |
|
Actavia Life Sciences Inc
RASP's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Actavia Life Sciences Inc 's sales fell
in II. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 0.34 %
Actavia Life Sciences Inc net loss decreased from $-4 millions, to $0 millions in II. Quarter 2024,
• More on RASP's Growth
|
|
Actavia Life Sciences Inc realized a net loss in trailing twelve months.
Actavia Life Sciences Inc realized cash reduction of $ -0 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 5983.03.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.
• More on RASP's Valuation
|
|
|
|
|
Actavia Life Sciences Inc realized net loss in trailing twelve months.
Actavia Life Sciences Inc realized cash outflow of $ -0per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 5983.03.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.
• More on RASP's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com